Karuna Therapeutics Inc. (KRTX) Climbs 58% After KarXT Meets Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia

November 18, 2019 7:17 AM

Karuna Therapeutics (NASDAQ: KRTX) Climbs ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found